taulogo

Company News

 

Pfizer’s Senior Director Frank Orlowski
Joins Board Of Advisors. View


2014 – 2015 Financials Reported – Company On Track To Regain Reporting Status. View


Tauriga Sciences Inc. Issues Comprehensive Update to Shareholders and Reports Significant Progress on Multiple Fronts.   View

LATEST TAURIGA SCIENCES UPDATES

Tauriga Sciences Inc. Completes the Successful Re-Audit of Its Fiscal Year 2014 Financial Statements and Files Its Fiscal Year 2015 Form 10K; Company On Track to Regain Fully Reporting 

 

NEW YORK, NY–(Marketwired – May 23, 2016) – Tauriga Sciences, Inc. (OTC PINK: TAUG) (“Tauriga” or the “Company”), a diversified life sciences technology Company, today announced that it has

Read More

TAURIGA SCIENCES INC. COMPLETES $105,500 USD EQUITY PRIVATE PLACEMENT WITH ACCREDITED INDIVIDUAL INVESTORS

 

NEW YORK, NY–(Marketwired – Apr 18, 2016) – Tauriga Sciences, Inc. (OTC PINK: TAUG) (“Tauriga” or the “Company”), a diversified life sciences technology Company, today announced that it has completed an equity private placement for $105,500 USD to date comprised of accredited individual investors as…

Read More

Tauriga Sciences Inc. Issues Comprehensive Update to Shareholders and Reports Significant Progress on Multiple Fronts


NEW YORK, NY–(Marketwired – Jun 1, 2016) – Tauriga Sciences, Inc. (OTC PINK: TAUG) (“Tauriga” or the “Company”), a diversified life sciences technology Company, today issued a comprehensive update to shareholders… 

Read More

Fully committed to commercializing innovation to enhance personal wellness, improve our environment and create lasting shareholder value.

Balanced Innovation and Commercialization

Tauriga Sciences, Inc. (TAUG) is a diversified life sciences company focused on generating profitable revenues in the natural wellness sector and on developing a proprietary synthetic biology platform technology through its wholly-owned Pilus Energy subsidiary.

The Company’s business model is to create an attractive and balanced portfolio of life sciences assets without typical clinical regulatory timelines.

box2
Tauriga’s main focus for the last year has been getting audited financials and relisted on BB. Due to what we believe was gross malpractice by our auditors, TAUG was delisted from the BB. But we are always looking for exciting opportunities to increase shareholder value.
box2a
Tauriga Sciences, Inc. (OTC PINK: TAUG) (“Tauriga” or the “Company”), a diversified life sciences technology Company, today announced that it has completed an equity private placement for $105,500 USD to date comprised of accredited individual investors as well as one institutional investor.
box3
Recently the Company added Frank Orlowski, Sr. Director at Pfizer (PFE); and Keith Berman  CEO of Digital Diagnostics Inc (DECN). The Company remains committed to finding the right opportunity to joint venture or merge with.